There may be two distinct subtypes of multiple sclerosis, according to a new study led by scientists at University College ...

Multiple sclerosis (MS) is a chronic autoimmune disease in which the immune system attacks the body’s nerves. Immune cells ...

Quantum Biopharma expects data from two now-completed, FDA-requested toxicology studies to support clinical testing of its ...

The ratio between two signaling molecules may be a key marker of MS brain inflammation and help identify candidates for BTK ...

Lipoic acid offers no improvements in walking speed or other outcomes in patients with progressive multiple sclerosis ...

Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...

—Clinicians may be underestimating the cognitive burden on patients with MS, underscoring the need for more comprehensive cognitive assessments and assessing patient-reported outcomes. A growing body ...

Many people with multiple sclerosis struggle with balance and coordination, and this study uncovers a hidden reason why.

The FDA rejected Sanofi's MS drug tolebrutinib, citing liver injury risks, unclear benefits, and trial data that failed to ...

A new study has discovered a possible biomarker linked to multiple sclerosis disease progression that could help identify ...

Resistance training is effective for improving gait speed in individuals with multiple sclerosis. The intensity and duration of resistance training are important factors in determining the magnitude ...